Drug Trial Radar · NCT07128550
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Dec 2026
Study completion Jul 2031
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Conditions
- Viral Hepatitis
Interventions
TobevibartDrug
Tobevibart administered by subcutaneous injection
ElebsiranDrug
Elebsiran administered by subcutaneous injection
BulevirtideDrug
Bulevirtide administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24Time frame: Week 24
- HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.Time frame: 24 Weeks after End of Treatment
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
Investigative Site
Innsbruck, Austria
Investigative Site
Vienna, Austria
Investigative Site
Bobigny, France
Investigative Site
Clichy, France
Investigative Site
Créteil, France
Investigative Site
Le Chesnay, France
Investigative Site
Limoges, France
Investigative Site
Lyon, France
Investigative Site
Montpellier, France
Investigative Site
Pessac, France
Investigative Site
Rennes, France
Investigative Site
Toulouse, France
Investigative Site
Villejuif, France
Investigative Site
Berlin, Germany
Investigative Site
Essen, Germany
Investigative Site
Frankfurt am Main, Germany
Investigative Site
Hanover, Germany
Investigative Site
Bergamo, Italy
Investigative Site
Foggia, Italy
Investigative Site
Milan, Italy
Investigative Site
Milan, Italy
Investigative Site
Pisa, Italy
Investigative Site
Torino, Italy
Investigative Site
Torino, Italy
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Craiova, Romania
Investigative Site
Barcelona, Spain
Investigative Site
Barcelona, Spain
Investigative Site
Madrid, Spain
Investigative Site
Madrid, Spain
Investigative Site
Santander, Spain
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Investigative Site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.